Skip to main content
Premium Trial:

Request an Annual Quote

NetGenics CFO Resigns to Join Phase-1 as CEO

NEW YORK, March 23 – Vincent Kazmer said Friday he was resigning as chief financial officer of NetGenics to join Phase-1 Molecular Toxicology as CEO.

“Phase-1 is a good opportunity,” Kazmer said. His resignation is effective immediately and he will start work at Phase-1 Molecular Toxicology in April.

The company, which is based in Santa Fe, NM, uses gene expression technologies and bioinformatics to help improve lead optimization and diminish toxic effects early in a drug’s development.

Phase-1’s founder Spencer Farr will head the company’s R&D division.

"As the company continues to expand its operations and business into Europe and Japan, and seeks to capitalize on the significant opportunities at hand, it is crucial to have a seasoned business leader at the helm,” Farr said.

Prior to joining NetGenics Kazmer was CEO of Lark Technologies, a publicly traded molecular biology contract research organization. 

NetGenics has not yet named a replacement for Kazmer. The Cleveland-based bioinformatics company recently laid off 29 of its 100 employees due to the downturn in the economic conditions, which forced the company to delay its IPO.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.